Cancer Genetics and Epigenetics, 2025, Vol.13, No.3, 136-144 http://medscipublisher.com/index.php/cge 143 Aghebati-Maleki L., Aghebati-Maleki A., Sarkesh A., Sorkhabi A., Khosroshahi L., Mardi A., and Baradaran B., 2023, The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies, Frontiers in Immunology, 14: 1113882. https://doi.org/10.3389/fimmu.2023.1113882 Chen T., 2024, Single-cell RNA sequencing reveals new insights into tumor heterogeneity, Cancer Genetics and Epigenetics, 12(1): 55-65. https://doi.org/10.5376/cge.2024.12.0007 Chen S., Zhang H., Zhang X., Xiao Y., and Zhu L., 2022, CAR-T cell therapy in hematological malignancies: current opportunities and challenges, Frontiers in Immunology, 13: 927153. https://doi.org/10.3389/fimmu.2022.927153 Chen Y., Zhao Z., Wu M., Francisco N., and Zhang Y., 2018, The application of CAR-T cell therapy in hematological malignancies: advantages and challenges, Acta Pharmaceutica Sinica B, 8: 539-551. https://doi.org/10.1016/j.apsb.2018.03.001 Clubb J., Chen Y., and Hong M., 2020, Engineering CAR-T cells for next-generation cancer therapy, Cancer Cell, 38(4): 473-488. https://doi.org/10.1016/j.ccell.2020.07.005 Chohan K.L., Siegler E.L., and Kenderian S.S., 2023, CAR-T Cell therapy: the efficacy and toxicity balance, Current Hematologic Malignancy Reports, 18(2): 9-18. https://doi.org/10.1007/s11899-023-00687-7 Dipersio J., and Ali A., 2024, ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights, Frontiers in Immunology, 15: 1432799. https://doi.org/10.3389/fimmu.2024.1432799 Gao L., Li X., Zhang X., Zhang C., He Y., Zhu W., Liu Y., Huang R., Zhong J., Wen Q., and Gao L., 2020, Recent advances in CAR-T cell engineering, Journal of Hematology and Oncology, 13(1): 86. https://doi.org/10.1186/s13045-020-00910-5 Gómez M., López-Matencio J., Castañeda S., De Soria G., Alañón-Plaza E., and Muñoz‐Calleja C., 2021, Monitoring and safety of CAR-T therapy in clinical practice, Expert Opinion on Drug Safety, 21: 363-371. https://doi.org/10.1080/14740338.2021.1979958 Goyco Vera D., Waghela H., Nuh M., Pan J., and Lulla P., 2024, Approved CAR-T therapies have reproducible efficacy and safety in clinical practice, Human Vaccines and Immunotherapeutics, 20(1): 2378543. https://doi.org/10.1080/21645515.2024.2378543 Gumber D., and Wang L., 2022, Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion, EBioMedicine, 77: 103941. https://doi.org/10.1016/j.ebiom.2022.103941 Gómez-Melero S., Hassouneh F., Vallejo-Bermúdez I.M., Agüera-Morales E., Solana R., and Caballero-Villarraso J., 2025, Tandem CAR-T cell therapy: recent advances and current challenges, Frontiers in Immunology, 16: 1546172. https://doi.org/10.3389/fimmu.2025.1546172 Hackett C., Brentjens R., and Rafiq S., 2019, Engineering strategies to overcome the current roadblocks in CAR T cell therapy, Nature Reviews, Clinical Oncology, 17: 147-167. https://doi.org/10.1038/s41571-019-0297-y Han D., Ye Z., Qian Q., Xu Z., and Yuan Z., 2021, Current progress in CAR-T cell therapy for hematological malignancies, Journal of Cancer, 12: 326-334. https://doi.org/10.7150/jca.48976 Hashem S., Chauhan R., Dagar G., Gupta A., Bagga P., Akil A., Haris M., Dagar M., Masoodi T., Macha M., Merhi M., Kumar R., Nisar S., Mirza S., Bhat A., Singh M., and Uddin S., 2023, Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments, Journal of Translational Medicine, 21(1): 449. https://doi.org/10.1186/s12967-023-04292-3 Holstein S., and Lunning M., 2020, CAR T-cell therapy in hematologic malignancies: a voyage in progress, Clinical Pharmacology and Therapeutics, 107(1): 112-122. https://doi.org/10.1002/cpt.1674 Hutton B., Kekre N., Lalu M., Grigor E., Daugaard M., Fergusson D., Atkins H., Montroy J., Seftel M., Presseau J., Thavorn K., and Holt R., 2019, Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis, Transfusion Medicine Reviews, 33(2): 98-110. https://doi.org/10.1016/J.TMRV.2019.01.005 Haslauer T., Greil R., Zaborsky N., and Geisberger R., 2021, CAR T-cell therapy in hematological malignancies, International Journal of Molecular Sciences, 22(16): 8996. https://doi.org/10.3390/ijms22168996 Kong Y., Li J., Zhao, X., Wu Y., and Chen L., 2025, CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity, Frontiers in Immunology, 15: 1519671. https://doi.org/10.3389/fimmu.2024.1519671 Kampouri E., Little J.S., Rejeski K., Manuel O., Hammond S.P., and Hill J.A., 2023, Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies, Transplant Infectious Disease, 25: e14157. https://doi.org/10.1111/tid.14157
RkJQdWJsaXNoZXIy MjQ4ODYzNA==